• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Endocrinology

Intranasal glucagon may be effective in the treatment of hypoglycemia in type 1 diabetes

byDeepti Shroff KarhadeandDavid Wang
March 12, 2016
in Endocrinology, Pediatrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a prospective cohort of 48 youths with type 1 diabetes mellitus (T1DM), use of needle-free glucagon nasal powder demonstrated similar pharmacokinetic and pharmacodynamics properties as intramuscular glucagon.

2. The adverse effects of both intranasal and intramuscular administration were transient and similar in frequency.

Evidence Rating Level: 2 (Good)

Study Rundown: Hypoglycemia is a life-threatening complication of T1DM resulting in sudden loss of consciousness and seizures. The current treatment for hypoglycemia in patients with T1DM outside the hospital setting involves the administration of intramuscular glucagon. However, previous observational trials have demonstrated significant difficulty with glucagon injections in the community due to improper technique. The purpose of this trial was to assess the pharmacodynamics and pharmacokinetic properties of a needle-free intranasal glucagon in youths with T1DM.

The study prospective recruited 48 participants between the age of 4 and 17 years of age. Each participant received either a weight-based dose of intranasal glucagon or a varying dose of intranasal glucagon. At the conclusion of the trial, both intramuscular and intranasal glucagon produced a significant increase in serum glucose levels within 20 minutes of administration. Additionally, serum glucagon levels, as well as time to peak plasma glucose, were similar between both groups. Overall, adverse events were similar between the 2 groups, with the intranasal group demonstrating a significant reduction in transient nausea compared to the intramuscular group. The result of this trial support the use of intranasal glucagon as a potential needle-free method in the treatment of hypoglycemia in youths with T1DM. However, the study was performed in fasting participants and does not represent efficacy of treatment for hypoglycemic episodes. Additional trials for real-life applications for treatment of hypoglycemia in patients with T1DM will help to confirm the effectiveness of intranasal glucagon.

Click to read the study in Diabetes Care

Relevant Reading: Intranasal glucagon: a promising approach for treatment of severe hypoglycemia

RELATED REPORTS

#VisualAbstract: Continuous glucose monitoring in type 1 diabetes results in improved blood glucose levels

Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases

Faricimab may improve visual acuity in patients with diabetic macular edema

In-Depth [prospective cohort]: This study included 48 children aged 4 to 17 years old with known T1DM. Key exclusion criteria included previous history of severe hypoglycemic episode or known history of epilepsy or seizures. The participants were divided into three cohorts based on age: 1) age 4 to <8, 2) age 8 to <12, and 3) age 12 to <17 years of age. The participants in the first 2 cohorts were randomly assigned to either received a weight based dose of intranasal glucagon or either 2mg or 3mg of intranasal glucagon in two separate session. The third cohort received 1mg intramuscular glucagon in the first session and 3mg intranasal glucagon in the second. All participants were provided a bolus of insulin to achieve a glucose nadir of <80 mg/dL prior to the study. Serial blood draws up to 90 minutes were performed after the administration of glucagon. The outcome of interest were the pharmacodynamics and pharmacokinetic properties of both intramuscular and intranasal glucagon, including glucagon levels and time to peak plasma glucose. At the conclusion of the trial, there were no significant difference in the number of participants who achieved a >25 mg/dL rise in serum glucose between both the intranasal and intramuscular glucagon groups. Additionally, there were no differences between the 2 groups with respect to maximum plasma glucose, or time to achieve maximum serum concentration of glucagon. With respect to adverse events, there was no difference between the two groups with respect to head/facial discomfort (p = 0.30). However, there was a significant reduction in the frequency of nausea experienced by the intranasal group versus the intramuscular group (p = 0.05).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: glucagonType 1 Diabetes Mellitus
Previous Post

Younger sibling presence associated with improved BMI trajectory

Next Post

Late pregnancy pertussis vaccination may boost passive immunity

RelatedReports

#VisualAbstract: Continuous glucose monitoring in type 1 diabetes results in improved blood glucose levels
StudyGraphics

#VisualAbstract: Continuous glucose monitoring in type 1 diabetes results in improved blood glucose levels

October 28, 2022
Long-term outcomes for off-pump and on-pump CABG are similar
Cardiology

Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases

September 14, 2022
Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab may improve visual acuity in patients with diabetic macular edema

March 8, 2022
Insulin costs rose exponentially, regardless of formulation or patent
Chronic Disease

Increased prevalence of type 1 and type 2 diabetes observed in youths in the United States, 2001 to 2017

September 1, 2021
Next Post
Late pregnancy pertussis vaccination may boost passive immunity

Late pregnancy pertussis vaccination may boost passive immunity

Increased severe maternal morbidity with multiple gestation pregnancies

Pessary for short cervix may reduce risk of twin preterm birth

Combination antibiotics before C-section may reduce risk of endometritis

Combination antibiotics before C-section may reduce risk of endometritis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options